Citius Oncology, Inc.

192 articles about Citius Oncology, Inc.

• Citius Pharmaceuticals to Present Update on Proprietary Product Candidates at Two Virtual Conferences in January

  1/6/2021

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will be presenting at two virtual investor conferences during the month of January 2021 . H.C. Wainwright BioConnect 2021 Virtual Confere

• Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19

  12/15/2020

  - Infectious Disease experts provide review of CLABSI patient management in a restricted environment - CLABSI case histories reviewed and discussed

• Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap

  12/9/2020

  -- Mino-Wrap's novel approach to reducing post-mastectomy infections associated with the use of a tissue expander is on track in its preclinical stage -- Some next steps for Mino-Wrap development include designing and executing a large animal study and the clinical plan

• Citius Pharmaceuticals Subsidiary NoveCite Announces Data from a Study of Induced Mesenchymal Stem Cell ("i-MSC") Therapy in an in vivo Model of Acute Respiratory Distress Syndrome ("ARDS")

  12/8/2020

  --Interim results indicate i-MSC therapy improves oxygenation and reduces lung injury --Efficiently manufactured higher potency mesenchymal stem cells offer promising therapeutic approach

• Citius Pharmaceuticals to Present Corporate Update at Benzinga Global Small Cap Conference on December 8

  12/3/2020

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will be participating in the Benzinga Global Small Cap Conference being held virtually on December 8 and 9, 2020

• Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components

  11/30/2020

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced the completion of a Boston Analytical study "Silicone Disk Method for In Vitro Assessment of Antimicrobial Activity Against Resistant Staphylococcal Biofilms by Minocycline-EDTA-Ethanol and EDTA-Ethanol Lock Solutions."

• Citius Pharmaceuticals to Present at Virtual Fall Investor Summit

  11/10/2020

  Mino-Lok, Company's lead product, is progressing through Phase 3 trials and to be positioned for market entry into an estimated $1.5 billion market

• Citius Pharmaceuticals to Present at H.C. Wainwright 6th Annual Israel Conference

  11/9/2020

  Anticipates response on pre-investigational new drug (PIND) guidance from the FDA in November 2020 to proceed with Clinical Development Program for Mino-Wrap

• Citius Pharmaceuticals Issues October 2020 Letter to Shareholders

  10/27/2020

  -- Company recently licensed cellular therapy for potential treatment of ARDS associated with COVID-19 -- Mino-Lok, Company's lead product, is progressing through Phase 3 trials and, if approved, is positioned for market entry into an estimated $1.5 billion market -- Phase 2b trial for Halo-Lido hemorrhoid treatment expected to begin Q1 2021

• Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) and Other Acute Respiratory Conditions

  10/13/2020

  - Novellus's iMSCs are derived from a single donor using its patented mRNA-based, footprint-free cell reprogramming technology - iMSCs overcome the significant challenges of limited supply and low potency associated with donor-derived MSCs   [13-October-2020]   CAMBRIDGE, Mass. , Oct. 13, 2020 /PRNewswire/ -- Novellus Therapeutics ("Novellus"), an engineered cel

• Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)

  10/7/2020

  NC-iMSCs demonstrate higher potency, uniformity and consistency - significant advantages over donor derived MSCs

• Citius's Mino-Lok trial sites resupplied with registration batch product

  9/30/2020

  Citius Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced that the Mino-Lok Clinical Trial Material at each of the clinical sites has been replaced with registration batch product.

• Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial

  9/29/2020

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announce

• Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok®

  9/22/2020

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has achieved a number of significant milestones over the past several weeks for Mino-Lok®.

• Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance

  9/15/2020

  Citius Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced that it has filed an amendment to its Mino-Lok phase 3 protocol.

• Citius Pharmaceuticals to Present at H.C. Wainwright Virtual 22nd Annual Global Investment Conference

  9/8/2020

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that its management is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference

• Citius Pharmaceuticals to Present at the LD 500 Virtual Conference

  8/27/2020

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that it will be presenting at the 12th annual LD 500 conference on Tuesday, September 1, at 11:00 AM ET.

• Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap

  8/26/2020

   Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced that it has

• Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo

  8/13/2020

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the company will deliver a presentation at the MoneyShow Las Vegas Virtual Expo that is being held August 18 – 20, 2020.      E

• Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering

  8/5/2020

  Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC